Background: Clostridioides difficile infection (CDI) is on the rise.
C lostridioides difficile is the most common cause of health care-associated infections (HAIs) in the United States and is classified as an urgent threat by the Centers for Disease Control and Prevention (CDC) in its antimicrobial resistance threat report in 2013 (1, 2) . The incidence of C difficile infection (CDI) increased progressively during the first decade of this century, at times with dramatic outbreaks of severe CDI (3, 4) . It was estimated in 2011 that there were over 450 000 incident cases of CDI in the United States, which were associated with over 29 000 deaths and over $5.9 billion in excess health care costs (5, 6) . The incidence of CDI has remained stubbornly elevated since (7) .
With these increases in CDI incidence and severity, numerous gaps in CDI prevention efforts were identified. First, there were no standardized surveillance definitions or systematic efforts for CDI surveillance, which may have impeded recognition of the changes in CDI epidemiology and prevention efforts (8) . Second, variability in CDI prevention efforts were also recognized, including not routinely placing all patients with CDI into contact precautions (9) . To address these gaps, standardized CDI surveillance definitions were proposed, and recommended basic and special approaches to prevent CDI were published (8, 10) . To further facilitate CDI prevention efforts, the Centers for Medicare & Medicaid Services (CMS) mandated acute care hospital CDI reporting to the CDC National Healthcare Safety Network (NHSN) in 2013, the results of which are available to the public through the CMS Hospital Compare Web site. The CMS also uses these data for value-based purchasing calculations, so an elevated CDI incidence may negatively affect CMS payments to a hospital (11) .
Despite efforts to improve CDI prevention, many hospitals continue to have an elevated CDI incidence, and C difficile remains the most common cause of HAIs in the United States (12, 13) . To improve CDI prevention efforts at hospitals with persistently elevated CDI incidence, the CDC funded the STRIVE (States Target-
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Web-Only CME/MOC activity ing Reduction in Infections via Engagement) program, led by the American Hospital Association's Health Research & Educational Trust. The goals of this program were to 1) prevent HAIs through improved infection control practices and 2) facilitate and foster relationships among state hospital associations, state health departments, and other key HAI prevention stakeholders.
METHODS
The STRIVE initiative aimed to accomplish several goals (14) . Improving implementation of infection prevention and control (IPC) efforts was prioritized, by providing and coaching participants on use of IPC assessment tools and the CDC's Targeted Assessment for Prevention strategy resources, as well as providing technical assistance to improve IPC practices. The STRIVE initiative also aimed to strengthen relationships between state-level partnerships, such as state hospital associations and state health departments, to both help sustain improvements from this project and bolster the foundation for rapid response and cooperation between statelevel partners and hospitals when challenged with new infectious hazards. As improving implementation of IPC practices was a priority in hospitals with a disproportionately high burden of HAIs, rates of CDI, central lineassociated bloodstream infection, catheter-associated urinary tract infection, and methicillin-resistant Staphylococcus aureus bloodstream infection were chosen as measures to evaluate the STRIVE initiative's success.
In this article, we describe the CDI quantitative results of 3 cohorts of this collaborative, which were recruited between November 2016 and May 2018. The qualitative assessment results for this collaborative are detailed elsewhere (15) .
Data Sources
Data for this analysis came from 3 sources. First, quantitative CDI outcome data were obtained as reported by participating STRIVE hospitals to the NHSN surveillance program (that is, laboratory-identified, hospital-onset CDI) (16) . Second, hospital characteristics, such as number of beds, teaching status, urban or rural location, ownership, and hospital type, were obtained from the 2015 American Hospital Association Annual Survey of Hospitals (17) . The STRIVE initiative included 3 hospital types: acute care, long-term acute care, and critical access hospitals; the latter term is a CMS designation for hospitals with 25 or fewer inpatient beds, short lengths of stay, and located more than 35 miles from the nearest hospital. Hospitals participating in STRIVE were asked to complete a gap assessment tool at baseline and at the end of the intervention period to assess HAI prevention practices, policies, and procedures. Facilities could complete either the CDC Infection Control Assessment and Response (ICAR) tool (18) or the Practice Change Assessment (PCA), which was a shortened version of the ICAR developed for this project. The gap assessment tool was implemented in coordination with state partners, who visited sites and assisted with reporting on existing practices in each facility.
Study Design and Cohort Recruitment
This was a prospective, nonrandomized, externally facilitated quality improvement initiative, targeting acutecare, long-term acute care, and critical access hospitals clustered within states. Both intensive care units and nonintensive care units participated. Hospitals with a high burden of CDI as well as high burden of central line-associated bloodstream infection, catheter-associated urinary tract infection, or hospital-onset methicillin-resistant S. aureus bloodstream infection were targeted for recruitment. "High burden" of HAI was defined as having a cumulative attributable difference above the first tertile (that is, the worst one third) in the CDC's Targeted Assessment for Prevention strategy (19) . The cumulative attributable difference is obtained by subtracting a numerical prevention target (that is, the product of a predicted number of HAIs and a standardized infection ratio goal based on NHSN targets from the Department of Health and Human Services) from an observed number of HAIs. Once word of STRIVE began to circulate, nontargeted hospitals (for example, those that may not have had a high HAI rate) that felt they could benefit from the resources and efforts also volunteered to participate. Additional details of the recruitment strategy are published elsewhere (14) .
A pilot cohort was recruited in June 2016 and was active over 10 months, to inform and refine the recruitment, intervention, and implementation strategy for the project. We analyze and describe the results from the 3 later cohorts with a 12-month pre-and postintervention period, active between November 2016 and May 2018.
The University of Michigan Medical School Institutional Review Board reviewed the study and determined that it did not meet the regulatory definition of research involving human subjects.
Intervention
The intervention available to all participating hospitals included several components that are summarized here briefly; the development process and further details are published elsewhere (14, 20 -22) . The ICAR/ PCA was provided to help hospitals identify general infection control gaps as well as HAI-specific gaps so as to identify and prioritize interventions for implementation. Web-based and brief on-demand modules, including modules for onboarding participating hospitals, providing education on "foundational" or horizontal infection control practices (such as hand hygiene, personal protective equipment, and antimicrobial stewardship), HAIspecific prevention strategies, and the CDC's Targeted Assessment for Prevention strategy resources, were developed for sites.
The recommended HAI-specific prevention strategies were organized by using a 2-tier approach (23). Tier 1 focused on 5 basic prevention strategies; if rates of infection did not decline with these steps, a HAIspecific guide to patient safety self-assessment tool was offered as the first component of tier 2 (22) . The guide to patient safety was designed to help hospitals priori-tize HAI strategies, which could include refocusing on tier 1 interventions needing further attention or additional interventions within tier 2 that were potentially costlier and more resource-intensive than tier 1. Six Web-based, on-demand CDI modules were distributed to support these strategies. Within tier 1, CDI-specific interventions focused on antimicrobial stewardship, identification of appropriate patients for C difficile testing, contact precautions, and environmental disinfection. In contrast, CDI-specific prevention strategies for tier 2 began with the CDI guide to patient safety, followed by prolonged contact precautions while C difficile test results were pending, and targeted interventions to improve hand hygiene compliance and environmental disinfection. Monthly live webinars reinforced educational content and implementation strategies and provided coaching by subject matter experts. State partners were also required to lead at least 1 inperson meeting, as an opportunity to bring hospitals and state partners together to support building relationships in a protected time and space.
As part of STRIVE, state hospital associations were expected to conduct in-person site visits to at least one half of the hospitals that participated in their state. State hospital associations were frequently joined by their other state partners on these visits, which aimed to provide in-person technical assistance with STRIVE tasks (such as data submission) and also provide additional coaching to hospitals and units on IPC practices. Many state hospital associations used these site visits to perform the ICAR/PCA reports that let hospitals prioritize IPC prevention activities. There was no standardized process for how hospitals were selected for these visits.
An overview of the STRIVE project timeline is shown in Appendix Figure 1 (available at Annals.org).
Statistical Analysis
The primary outcome was the overall hospitalonset CDI rate, calculated as the number of hospitalonset CDIs per 10 000 patient-days from all hospital types studied (acute care, long-term acute care, and critical access). Per NHSN definitions, recurrent CDI is excluded from "hospital-onset CDI." Descriptive statistics with measures of variation (when feasible) were used to summarize participating hospital characteristics, as mean (SD), median (interquartile range), and number (percentage).
Hospital-onset CDI rate was reported monthly. Ninety-five percent CIs were calculated by using a bootstrap approach in which we resampled the data at each time point 10 000 times, recalculating the hospital-onset CDI incidence rate in each sample. A 95% normal CI was then calculated on the basis of the bootstrap estimates. To display aggregated pre-and postintervention data by hospital, we generated a Sankey bar graph in SAS (SAS Institute) by using the macro %sankeybarchart (24) . All analyses were conducted in Stata, version 13 (StataCorp); SAS, version 9.4; and R Project (R Foundation for Statistical Computing).
Role of the Funding Source
This study was funded by the CDC via a contract that specified program objectives and deliverables and general project oversight, and also enabled provision of NHSN data for outcome analysis. The CDC had no role in the design of the study, writing of the article, or analysis of the data.
RESULTS

Hospital Characteristics
A total of 404 hospitals were recruited, and 387 were retained from cohorts 2 through 4 from 23 states and the District of Columbia (Appendix Figure 2 , available at Annals.org). Of these, 366 (95.0%) reported CDI data for analysis ( Table 1 ). There were 257 (70.2%) acute care hospitals, 36 (9.8%) long-term acute care hospitals, and 73 (19.9%) critical access hospitals. The mean bed size was 239.1 (SD, 263.3), and 240 (68.8%) were in an urban location.
A total of 363 of the 366 hospitals that provided CDI data completed baseline ICAR/PCA assessments (99%). These assessments revealed several gaps regarding CDI policies and procedures. For example, although 93.4% of hospitals provided training on hand hygiene, only 37.2% assessed hand-hygiene competency. Similarly, 88.4% of respondents stated they provided training on donning and doffing personal protective equipment, but only 37.2% assessed donning and doffing competency. Training on environmental cleaning was provided by 86.5% of facilities; of these, 70.2% provided annual training, 65.8% assessed environmental cleaning competency, and 65.3% conducted audits of cleaning efficacy and provided feedback to environmental services personnel. Of note, 74.4% of hospitals 
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reported strategies to reduce use of antibiotics that are high risk for CDI (for example, fluoroquinolones, and extended spectrum cephalosporins), but only 24.5% provided feedback to prescribers about how to improve antibiotic prescribing. At the conclusion of hospital participation within a cohort, follow-up ICAR/PCA assessments were provided by 283 hospitals (77%). These follow-up assessments indicated moderate improvement in some practices. For example, assessment of hand-hygiene competency increased from 37.2% at baseline to 55.8% at follow-up. Similarly, assessment of donning and doffing of gowns and other personal protective equipment increased from 37.2% at baseline to 57.6% at follow-up.
Unadjusted Outcomes
In the preintervention period, there were 10 752 cases of hospital-onset CDI and 15 308 300 patientdays of observation, for an unadjusted hospital-onset CDI rate of 7.0 per 10 000 patient-days ( Table 2 ). In the postintervention period, there were 8668 hospital-onset CDI cases and 15 243 667 patient-days of observation, for an unadjusted hospital-onset CDI rate of 5.7 per 10 000 patient-days (Appendix Table 1 , available at Annals .org). Although the rate dropped, visualization of the CDI rate over time demonstrates this downward trend was constant, without an apparent change in slope or intercept associated with the intervention start (Appendix Figure 3 , available at Annals.org). Data for the subset of hospitals that indicated they focused on CDI prevention during STRIVE are presented in Appendix Table 2 and Appendix Figure 4 (available at Annals .org).
Rates during the pre-and postintervention periods and the change between the 2 periods at the hospital level are shown in the Figure and Appendix Table 3 (available at Annals.org). Eleven percent of reporting hospitals had hospital-onset CDI rates of zero during both periods, whereas 38% of hospitals hit the CDC reduction goal of 30% in the postintervention period relative to the preintervention period. Among the hospitals that hit the reduction goal, 76% were acute care, 63% were nonteaching, 73% were urban, and 63% were nongovernment, nonprofit hospitals.
DISCUSSION
Although we observed a statistically significant decline in the overall CDI rate in STRIVE, our multimodal educational and structural intervention did not appear to affect this trend. Rather, our findings mirror global secular trends of decreasing CDI observed in the CDC Emerging Infections Program data and NHSN (13, 25) . Even though we targeted hospitals struggling with CDI, there are several potential explanations as to why the intervention did not affect CDI rates. Collectively, STRIVE serves to highlight the challenges encountered when preventing CDI in health care settings, including those performing poorly in preventing HAIs.
One potential explanation for why STRIVE was negative is the era in which this intervention took place. Dramatic increases in CDI incidence and severity observed in the 2000s led to substantial efforts to prevent this infection. For example, the Society for Healthcare Epidemiology of America (SHEA) Compendium of Strategies to Prevent Health Care-Associated Infections published recommendations for acute care hospitals to implement for CDI prevention in 2008, and The Joint Commission used these for hospital accreditation (10) . These recommendations were reiterated in the 2010 SHEA/Infectious Diseases Society of America Clinical Practice Guidelines for CDI, and again when the SHEA Compendium was updated in 2014 (10, 26) . In addition, in 2013, CMS mandated CDI reporting to NHSN, and these data were to become publicly available and be used for value-based purchasing. Because the STRIVE program did not start until 2015 and many of the CDI prevention recommendations were based on the SHEA Compendium, it is likely that many, if not all, of the hospitals involved in the STRIVE CDI intervention had at least attempted some of these interventions. Thus, the general downward trend in CDI incidence observed may have represented the fruits of the pre-STRIVE labors, leading STRIVE to have had minimal impact on the observed rate of infections.
Another plausible explanation for why STRIVE was a negative study may be the relatively low quality of evidence to support CDI prevention recommendations. The 2017 update of the SHEA/IDSA Clinical Practice Guidelines underwent a formal GRADE (Grading of Recommendations, Assessment, Development and Evaluations) process to evaluate the quality of data behind all recommendations, including for CDI prevention (3). Only 1 recommendation-wearing gloves before contact with a patient with CDI-was given a "high" strength of evidence. Of note, the data to support this recommendation are based on a single-center study con- 
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ducted on 4 wards, so even these data have limitations (27) . Most CDI prevention recommendations are based on single-center, quasi-experimental interventions conducted in response to a CDI outbreak (28) . Many of these interventions have failed to consistently demonstrate reductions in CDI in endemic settings (29 -31) . Lack of high-quality data makes it challenging to know which recommendations to focus on or are most applicable to local CDI epidemiology. For example, in our study, there did appear to be improvement in some CDI prevention practices, such as assessment of hand hygiene and use of personal protective equipment; however, this did not result in substantial reduction of CDI incidence. Another challenge to CDI prevention is there is no single point in time (as there is for prevention of central line-associated bloodstream infection and surgical-site infection) for a "time-out" to ensure that a bundle of prevention measures supported by high-quality data is in place. Rather, every interaction with a patient colonized with C difficile can lead to contamination and potential for transmission to other patients. Along these lines, current CDI prevention recommendations appear to have a "floor" effect. Similar to this study, a collaborative of 35 hospitals in New York observed an overall reduction in CDI incidence over the entire study period, but the CDI rate trend line was uninterrupted by a similarly designed intervention to prevent C difficile transmission (32) . Of note, the higher the baseline CDI rate, the greater the reduction in hospital-onset CDI after the intervention. However, as the baseline CDI rate approached about 7 to 8 CDI cases per 10 000 patient-days, minimal further reductions in CDI incidence were observed. Rather, when the baseline CDI rate went below this level, some hospitals observed an increase in CDI (32) . Data from this collaborative of 35 hospitals suggest that strategies focusing on preventing C difficile transmission have a floor of 
(18%)
In this Sankey bar chart, the connecting segments show how hospitals changed from the pre-to the postintervention periods. The slopes of the connecting segments should be interpreted cautiously because some segments connecting to the same rate category are increasing or decreasing visually but indicate no change in rates in these hospitals. Only segments that connect to a different category indicate changes in rates from the preto the postintervention period. Data are from 365 hospitals. CDI = Clostridioides difficile infection.
Results of a Clostridioides difficile Infection Intervention approximately 7 cases per 10 000 patient-days. The overall CDI rate at the beginning of this study was 7.0 cases per 10 000 patient-days, suggesting that many of the hospitals participating in this study were already at, or approaching, their floor CDI rate. An encouraging finding of this study was 74.7% of hospitals with a baseline CDI rate of 6 or fewer cases per 10 000 patientdays had a postintervention rate equal to or lower than the baseline rate. Although most data are derived from quasiexperimental studies and occur in response to CDI outbreaks and/or excessively elevated CDI rates, antimicrobial stewardship is probably the most effective strategy to prevent CDI (3). The first line of defense against CDI is a healthy intestinal microbiome. Antimicrobials alter the composition of the intestinal microbial from one that protects against CDI to one that is permissive to, or even promotes, CDI (3). Reducing unnecessary antimicrobial exposures or shifting antimicrobial prescribing to agents associated with a lower risk for CDI will reduce the number of patients at risk for CDI and therefore reduce the number of patients that develop CDI. There are also benefits to other patients, because if fewer patients develop CDI, fewer patients will contribute to C difficile transmission. However, challenges to effective antimicrobial stewardship exist when it comes to CDI prevention. For instance, antimicrobial stewardship appears to be most effective if it targets antimicrobials to which C difficile strains are resistant (3, 33, 34) . However, most laboratories do not have expertise in isolating C difficile in culture and performing anaerobic susceptibility testing or strain typing, limiting the opportunities to optimize antimicrobial stewardship for CDI prevention (3) . Using clinical data to identify antimicrobials with strong associations with CDI at a single hospital is challenging as well, because local antimicrobial prescribing patterns will affect the associations and there may be too few CDI cases to have sufficient statistical power to identify associations. Because data on antimicrobial use were not collected for this study, it is not known whether the intervention affected antimicrobial prescribing practices.
Our study has limitations. Most important, we were unable to track fidelity to the intervention. Thus, we cannot say whether this study failed to improve CDI rates owing to lack of intervention implementation, lack of additional efficacy of the intervention beyond what the participating hospitals were already doing, or overall failure of the recommended practices on CDI. Along these lines, because data on antimicrobial use were not collected, it is not known whether the intervention affected antimicrobial prescribing practices. Another potential confounder that may have affected the efficacy of the intervention was type of C difficile diagnostic assay used at the participating hospitals. Because nucleic acid amplification tests are very sensitive, they are more likely to detect C difficile colonization present on admission in a patient with other causes of diarrhea (such as laxative use) than toxin detection assays, thus blunting the apparent efficacy of interventions designed to prevent C difficile transmission in the hospital. How-ever, analyses controlling for the type of diagnostic assay used were performed (not shown), and no differences in CDI incidence rate trends were observed by type of assay used. There were no inclusion criteria for participation in STRIVE, meaning that some hospitals may have started the program with already reduced CDI rates that could have limited the effect of the intervention. Patient-level data were not available to include in our analysis. Finally, the intervention and assessment period were short, and it may take longer to see an effect from STRIVE in hospitals.
In conclusion, the observed reduction in CDI rates observed in STRIVE mirrored global trends and did not appear to be related to the study intervention. Many gaps to CDI prevention remain. Higher-quality data of current CDI prevention recommendations are needed in order to better tailor efforts to local CDI epidemiology. In addition, new CDI prevention modalities, such as vaccination and microbiome sparing agents, are needed to overcome the limitations of our current efforts. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24 Educational intervention: live webinars, Web-based on-demand modules, CDC TAP strategy, selected site visits, monthly coaching calls, monthly Learning Action Forums, in-person meetings 
